Starting April 2024, NHS England will halt the prescription of puberty blockers for gender-dysphoric youth, as part of an updated approach to their care. This decision precedes the final Cass report, expected in April 2024, which may bring further changes. Cross-sex hormones will still be available for those around 16 years of age, with added safeguards. The new policies are aimed at providing more holistic and cautious care, moving away from the previous model focused primarily on medical transition for minors. This significant policy shift aligns with ongoing debates about the best approaches to support gender-dysphoric youth, reflecting a careful consideration of the treatments’ long-term impacts and the current state of evidence.
For a detailed overview, you can view the original source: SEGM.
+++